Monument Therapeutics Limited 11798829 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is research and experimental development on biotechnology. Digita Accounts Production Advanced 6.30.9574.0 true 11798829 2024-01-01 2024-12-31 11798829 2024-12-31 11798829 core:CurrentFinancialInstruments 2024-12-31 11798829 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 11798829 core:FurnitureFittingsToolsEquipment 2024-12-31 11798829 bus:SmallEntities 2024-01-01 2024-12-31 11798829 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 11798829 bus:FilletedAccounts 2024-01-01 2024-12-31 11798829 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 11798829 bus:RegisteredOffice 2024-01-01 2024-12-31 11798829 bus:Director1 2024-01-01 2024-12-31 11798829 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 11798829 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 11798829 core:PlantMachinery 2024-01-01 2024-12-31 11798829 1 2024-01-01 2024-12-31 11798829 6 2024-01-01 2024-12-31 11798829 countries:England 2024-01-01 2024-12-31 11798829 2023-12-31 11798829 core:FurnitureFittingsToolsEquipment 2023-12-31 11798829 2023-01-01 2023-12-31 11798829 2023-12-31 11798829 core:CurrentFinancialInstruments 2023-12-31 11798829 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 11798829 core:FurnitureFittingsToolsEquipment 2023-12-31 iso4217:GBP xbrli:pure

Registration number: 11798829

Monument Therapeutics Limited

Unaudited Financial Statements

for the Year Ended 31 December 2024

 

Monument Therapeutics Limited

Contents

Statement of Financial Position

1 to 2

Notes to the Unaudited Financial Statements

3 to 6

 

Monument Therapeutics Limited

(Registration number: 11798829)
Statement of Financial Position as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

1,826

1,086

Current assets

 

Debtors

5

359,799

107,295

Cash at bank and in hand

 

1,232,983

777,383

 

1,592,782

884,678

Creditors: Amounts falling due within one year

6

(189,291)

(127,195)

Net current assets

 

1,403,491

757,483

Net assets

 

1,405,317

758,569

Capital and reserves

 

Called up share capital

4,023

3,169

Share premium reserve

5,749,830

3,781,959

Retained earnings

(4,348,536)

(3,026,559)

Shareholders' funds

 

1,405,317

758,569

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Income Statement.

Approved and authorised by the Board on 6 May 2025 and signed on its behalf by:
 

 

Monument Therapeutics Limited

(Registration number: 11798829)
Statement of Financial Position as at 31 December 2024

.........................................
Dr J H Barnett
Director

   
     
 

Monument Therapeutics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Alderley Park
Congleton Road
Macclesfield
Cheshire
SK10 4TG

These financial statements were authorised for issue by the Board on 6 May 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention and on a going concern basis except that as disclosed in the accounting policies certain items are shown at fair value.

Other grants

Grant income is included in the profit and loss account on the accruals basis.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

Monument Therapeutics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

Straight line over 3 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 7 (2023 - 7).

 

Monument Therapeutics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 January 2024

3,854

3,854

Additions

1,878

1,878

At 31 December 2024

5,732

5,732

Depreciation

At 1 January 2024

2,768

2,768

Charge for the year

1,138

1,138

At 31 December 2024

3,906

3,906

Carrying amount

At 31 December 2024

1,826

1,826

At 31 December 2023

1,086

1,086

5

Debtors

Current

2024
£

2023
£

Prepayments

11,243

10,965

Other debtors

348,556

96,330

 

359,799

107,295

6

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Trade creditors

143,108

10,115

Taxation and social security

14,342

8,699

Accruals and deferred income

31,539

103,490

Other creditors

302

4,891

189,291

127,195

 

Monument Therapeutics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

7

Non adjusting events after the financial period

Since the year end the business successfully obtained further external investment of £848,309 to support its ongoing operations.